A mutual information-based in vivo monitoring of adaptive response to targeted therapies in melanoma

• Published in: Neoplasia (New York, N.Y.) Vol. 23; no. 8; pp. 775 - 782
• Main Authors: Bugi-Marteyn, Aurore, Noulet, Fanny, Liaudet, Nicolas, Merat, Rastine
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.08.2021; Neoplasia Press; Elsevier
• Subjects: Adaptive resistance; Algorithms; Animals; Biomarkers, Tumor; BRAF inhibitor; Disease Management; Disease Models, Animal; Disease Susceptibility; Drug Resistance, Neoplasm; ELAVL1/HuR; Gene Expression Regulation, Neoplastic - drug effects; Humans; Immunohistochemistry; Information theory; Melanoma; Melanoma - diagnosis; Melanoma - drug therapy; Melanoma - etiology; Melanoma - metabolism; Mice; Models, Theoretical; Molecular Targeted Therapy - adverse effects; Molecular Targeted Therapy - methods; Mutual information; Original Research; Protein Kinase Inhibitors - pharmacology; Protein Kinase Inhibitors - therapeutic use; Single-Cell Analysis - methods; Treatment Outcome; Xenograft Model Antitumor Assays; Adaptive resistance; BRAF inhibitor; ELAVL1/HuR; Mutual information; Melanoma; Information theory

•In vivo dependencies should be quantified in adaptive resistance mechanistic studies•Mutual information (MI) quantifies any type rather than just linear dependencies•MI outperforms classic expression correlation coefficients•Adaptive response to small-molecules inhibitors can be monitored in vivo u...